Clinical Trial Detail

NCT ID NCT01424982
Title Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

acute lymphocytic leukemia

Therapies

Pegfilgrastim

Cytarabine + Methotrexate + Ponatinib

Ponatinib + Vincristine

Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine

Leucovorin

Age Groups: adult

Additional content available in CKB BOOST